[Secondary osteoporosis due to systemic autoimmune diseases and rheumatic diseases].
Tanaka
Yoshiya
Y
First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications* / Q000188:drug therapy; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology; D001862:Bone Resorption / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D016207:Cytokines / Q000502:physiology; D004164:Diphosphonates / Q000627:therapeutic use; D006023:Glycoproteins / Q000502:physiology; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D018799:Intercellular Adhesion Molecule-1 / Q000502:physiology; D008019:Life Style; D053244:Osteoprotegerin; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor; D012216:Rheumatic Diseases / Q000150:complications* / Q000188:drug therapy; D013601:T-Lymphocytes / Q000276:immunology
D018501:Antirheumatic Agents; D016207:Cytokines; D004164:Diphosphonates; D006023:Glycoproteins; D006887:Hydroxycholecalciferols; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D018799:Intercellular Adhesion Molecule-1; D011239:Prednisolone; C008088:alfacalcidol